The need for new treatments of neurological diseases is growing with the increasing lifespan of the human population. Typically, therapeutic drugs are administered orally or by intravenous injection. However, the passage of blood solutes into the brain is tightly regulated by the blood-brain barrier (BBB). Only molecules of relatively small size enter the human brain by simple and passive diffusion or via membrane transport proteins. As a result, many potentially useful therapeutic agents are clinically ineffective because they cannot cross the BBB.
The aim of the Lundbeck Foundation Research Initiative on Brain Barriers and Drug Delivery (RIBBDD) is to provide new tools for drug delivery across the BBB. Our multidisciplinary research program combines research on drug transport systems with research on BBB function and the neurovascular unit, the cells most closely associated with the brain endothelium.
Our vision is to provide high quality research that will help patients with neurological disorders live a better life.
PhD defence: Nikolay Kutuzov
Jan 07, 2020
Nikolay Kutuzov will defend his PhD thesis...
Søren Grubb wins the “Best Presentation Award”
Nov 28, 2019
Søren Grubb, Assistant Professor from Martin Lauritzen Lab, received the “Best Presentation Award”...
RIBBDD BIANNUAL MEETING, NOVEMBER 2019
Nov 21, 2019
November 19-20, 45 members from the RIBBDD network met at The Mærsk Tower in Copengahen...
PhD defence: Charlotte Goldeman Andersen
Jul 02, 2019
Charlotte Goldeman Andersen will defend her PhD theisis...
RIBBDD biannual meeting, April 2019
May 10, 2019
On April 23-24, almost 50 members from the RIBBDD network met at Helnan Marselis Hotel in Aarhus...